Search

everythinglearnresearchcommunity

for

Search:↓

Loop diuretics may double bone loss in elderly men, finasteride lowers prostate cancer risk but may increase high-grade tumors, abarelix reduces testosterone quickly, and transdermal testosterone offers minimal sexual benefit for women.

Men with melanoma have a higher risk of later being diagnosed with prostate cancer.

Combining α-blockers and Finasteride is useful for treating small prostate enlargement.

SRD5A2 enzyme expression varies in benign prostates and can be influenced by inflammation, affecting treatment options.

5-Alpha reductase inhibitors are safe long-term but may be outdated for preventing less significant prostate cancer.

New treatments are making advanced prostate cancer management more complex but also more hopeful.

The IPP index is linked to storage symptoms and leftover urine, and may help manage urinary tract symptoms.

Serenoa repens may help with prostate issues, but more research is needed to confirm its effectiveness.

Combination therapy for BPH is more effective in certain men but may not be cost-effective due to minimal impact and potential side effects.

New tests detect finasteride and dutasteride in urine quickly and easily.

More men are using medication for benign prostatic hyperplasia, influenced by marketing and FDA approvals.

The effectiveness of finasteride for preventing chronic bacterial prostatitis is unclear.

Both dutasteride and finasteride improve urinary symptoms, but dutasteride may be better at reducing the risk of prostate surgery and sudden inability to urinate.

Dutasteride is more effective than finasteride for treating BPH without extra safety risks.

Alpha-blockers and Finasteride effectively manage BPH symptoms long-term.

Combining different treatments may be needed to effectively manage chronic prostatitis.

5-alpha reductase inhibitors may reduce bladder cancer recurrence and improve survival.

Two enzymes regulate androgen receptor activity, affecting treatments for androgen insufficiency and benign prostatic hyperplasia.

Patients follow treatment well, but many change medicines; good information helps compliance.

Dutasteride effectively treats benign prostatic hyperplasia, improving symptoms and quality of life.

Evidence-based urology improved treatment and quality of life for conditions like BPH by shifting from surgery to effective medications like finasteride and dutasteride.

These medications for BPH have known risks and may have new side effects.

SDG helps reduce BPH effects in rats.

Finasteride helps reduce prostate size and symptoms in BPH but is less effective than terazosin and works best for larger prostates.